Dermatology

/Dermatology
Dermatology 2018-07-20T09:34:08+00:00

Acne Treatment

Klox Technologies and LEO Pharma, a global leader in dermatology, created FB Dermatology, a specialized dermatology company to commercialize Kleresca for the treatment of moderate to severe acne.

Acne vulgaris affects 85% of individuals at some point in their lives. The fact that acne is so common makes it no less heart-breaking to the people who suffer from its physical manifestations such as clogging of the pores, long-term lesions and associated scarring the face, chest or back. Klox understands that acne is a serious medical condition and requires innovative treatments that work and provide long-lasting results, which is what motivated the development of Kleresca.

The treatment is simple and involves applying a thin layer of Kleresca gel to the skin that is to be treated. Then, it is illuminated for nine minutes to generate fluorescent energy designed to address several factors responsible for causing acne while minimizing scarring. Results show durable improvements in the skin that persist for several months after treatment completion.

Click here to visit www.Kleresca.com

Kleresca® Clinical Results

For best results, Kleresca treatment is performed twice a week for six weeks.

Individual results may vary.

Visit www.Kleresca.com to explore patient results and find your clinic.

“It has been challenging living with acne. I just wanted to hide myself in all pictures. Things have completely changed since then. The scarring in my face is completely gone. I forgot to wear make-up to

Amman, UK
90%

More than 9 out of 10 patients benefitted from at least 1 IGA* grade improvement of their acne compared to 73% in the control (standard of care) at week (6) six1

82%

There was a reduction of at least 40% in inflammatory acne lesion counts in 82% of patients compared to 46% in the control group at week 121

52%

More than half of patients benefited from at least 2 IGA* grade improvements of their acne compared to 18% in the control group at week 121

92%

92% of patients who benefitted from at least 2 IGA* grade improvements of their acne maintained their gains at week 242

92%

Excellent compliance rate throughout lengthy 24-week long study period in young patient population (mean age: 22 years)2

*IGA: Investigator’s Global Assessment Scale for Acne Severity

(1) Click here to view main acne study published in the International Journal of Dermatology 

(2) Click here to view extension acne study published in the International Journal of Dermatology

Kleresca® Skin Rejuvenation

Inspired by the technology that brought you the Kleresca Acne Treatment, Kleresca Skin Rejuvenation stimulates your skin’s own biological processes to improve complexion and skin quality by inducing collagen production at a cellular level. The treatment is performed once a week for four weeks. See for yourself at www.Kleresca.com.

Click here to view skin rejuvenation study published in Clinical, Cosmetic and Investigation Dermatology

Kleresca® Safety Profile

Kleresca® Treatments are not absorbed or metabolized by the skin and are considered to be a pleasant and comfortable experience by patients.

In clinical trials, Kleresca® showed high safety with no serious adverse events.

All side effects were transient, nonpermanent and did not require any intervention by the clinic.